Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Free Cash Flow (2016 - 2025)

Fortress Biotech has reported Free Cash Flow over the past 13 years, most recently at -$12.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$12.5 million for Q4 2025, up 2.81% from a year ago — trailing twelve months through Dec 2025 was -$65.8 million (up 17.97% YoY), and the annual figure for FY2025 was -$65.8 million, up 17.97%.
  • Free Cash Flow for Q4 2025 was -$12.5 million at Fortress Biotech, down from -$6.1 million in the prior quarter.
  • Over the last five years, Free Cash Flow for FBIO hit a ceiling of -$6.1 million in Q3 2025 and a floor of -$47.9 million in Q4 2022.
  • Median Free Cash Flow over the past 5 years was -$26.5 million (2024), compared with a mean of -$28.7 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 110.93% in 2022 and later surged 67.26% in 2025.
  • Fortress Biotech's Free Cash Flow stood at -$37.4 million in 2021, then fell by 28.32% to -$47.9 million in 2022, then grew by 27.06% to -$35.0 million in 2023, then skyrocketed by 63.08% to -$12.9 million in 2024, then grew by 2.81% to -$12.5 million in 2025.
  • The last three reported values for Free Cash Flow were -$12.5 million (Q4 2025), -$6.1 million (Q3 2025), and -$27.6 million (Q2 2025) per Business Quant data.